SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DanZ who wrote (190)2/4/1999 1:43:00 PM
From: Bengalus   of 5582
 
Dan,

A company needs to conduct clinical trials, even for a homeopathic product, if it plans to make any claims regarding its efficacy.

While Quigley's delivery method may seem indirect, it actually seems to work quite well if you understand the theory behind it (alluded to in my earlier post). Here's more from the Med. Hypothesis article I quoted earlier.

"If zinc ions indeed operate as postulated, it is logical to speculate on the efficacy of zinc salt solutions introduced by nasal spray or drip. This approach has been tried a number of times, but has not succeeded because of moderate to severe tissue irritation caused by this direct application to nasal tissues. Although the oral route employing the lozenges would seem to be less direct, it now appears to be fraught with fewer unwanted side effects."

Of course, one of the co-authors of this study is JC Godfrey, the main Quigley patent holder.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News